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Abstract
Background: Emerging research on the mechanisms of disease chronicity in experimental arthritis has included a
new focus on the draining lymph node (LN). Here, we combined clinical-serological analyses and power Doppler
ultrasound (PDUS) imaging to delineate noninvasively the reciprocal relationship in vivo between the joint and the
draining LN in patients with rheumatoid arthritis (RA).
Methods: Forty consecutive patients refractory to conventional synthetic disease-modifying anti-rheumatic drugs
were examined through parallel PDUS of the hand–wrist joints and axillary LNs and compared with 20 healthy
subjects. A semiquantitative score for LN gray-scale (GS) parameters (nodal hypertrophy and cortical structure) and
LN PD signal was developed. A 6-month follow-up study with serial sonographic assessments was then performed
on initiation of tumor necrosis factor (TNF) inhibitors.
Results: PDUS analysis of RA axillary LNs revealed the existence of marked inter-individual heterogeneity and of
quantitative differences compared with healthy individuals in both GS and PD characteristics. RA LN changes were
plastic, responsive to anti-TNF treatment, and displayed a degree of concordance with synovitis activity in peripheral
joints. However, low LN PD signal at baseline despite active arthritis was strongly associated with a poor clinical
response to TNF blockade.
Conclusions: PDUS analysis of the draining LN in RA allows capture of measurable inter-individual differences and
dynamic changes linked to the underlying pathologic process. LN and joint sonographic assessments are nonredundant
approaches that may provide independent perspectives on peripheral disease and its evolution over time.
Keywords: Lymph node, Ultrasonography, Rheumatoid arthritis
* Correspondence: antonio.manzo@unipv.it
1Rheumatology and Translational Immunology Research Laboratories (LaRIT)
and Biologic Therapy Unit, Division of Rheumatology, IRCCS Policlinico San
Matteo Foundation/University of Pavia, P.le Golgi 19, 27100 Pavia, Italy
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Manzo et al. Arthritis Research & Therapy  (2016) 18:242 
DOI 10.1186/s13075-016-1142-7
Background
The juxta-articular lymphoid system (JLS) is a complex
of immunocompetent structures composed of the afferent
lymphatic network and the draining lymph node (LN)
chains [1]. These are fixed environments functionally con-
nected to the periphery, acting as complementary check-
points through progressive steps of the inflammatory
cascade, including the egress of cells and fluids from the
periphery [2], lymphocyte polarization and memory im-
printing [3], and peripheral tolerization [4, 5]. In keeping
with these concepts, the JLS has been shown to play key
roles in experimental arthritis, both in the development
of arthritogenic autoimmunity [6] and in the remote
control of peripheral inflammation through compensatory
drainage [7–9].
Circumstantial evidence supporting the participation
of the draining LN in rheumatoid arthritis (RA) derives
from independent studies performed over the last decades.
Lymphadenopathy has been recognized as a possible extra-
articular manifestation of the disease [10]. 18F-FDG PET
hypercaptation in axillary LN is detectable in patients with
active pathology [11]. Accordingly, prenodal lymph from
RA joints is characterized by increased flow rate and cyto-
kine concentration compared with controls [12]. Despite
these data, the relationship between chronic synovitis and
JLS involvement, including its clinical significance, remains
almost completely unexplored.
One of the main challenges in this direction is the
limitation in assessing the joint-draining LN complex in
vivo through multisite and serial analyses. Power Doppler
ultrasonography (PDUS) is a cheap, rapid, noninvasive, and
sensitive imaging technique extensively used to visualize
signs of joint inflammatory activity [13]. These signs in-
clude tissue hypertrophy and altered microperfusion
assessed through codification of the power spectral density
of the Doppler signal [14]. Of note, tissue swelling and vas-
cular flow enhancement are not restricted to inflamed per-
ipheral tissues, but are similarly induced during LN
immune-inflammatory challenge. Nodal response to
lymph-borne stimuli actually involves a sequence of plastic
events characterized by remodeling of the feed arteriole
[15], increased lymphocyte recruitment [15], expansion of
the vascular-stromal compartment [16, 17], and decreased
cell exit (“shut-down”) [18], ultimately leading to increased
blood flow, enlargement of the lymphocyte-rich cortex,
and LN hypertrophy [15, 19–22]. Supporting the value of
PDUS to visualize these processes, the sonographic assess-
ment of nodal dimensions, internal structure, and perfu-
sion is an established component of cancer diagnostic
work-up, being exploited to screen signs of metastasis or
inflammatory reactivity [23].
We have recently obtained preliminary evidence that
axillary LN PDUS can allow the detection of qualitative
modifications also in patients with RA [24]. To what
extent the analysis of the draining LNs can be applied to
delineate inter-individual differences or dynamic changes
in the course of the disease, and whether it provides
novel, relevant information, remains undetermined.
To address this question, we performed an integrated
analysis of the hand, wrist, and axillary LN ultrasono-
graphic (US) characteristics in patients with active disease,
exploring prospectively two primary issues: the spectrum
of structural and vascular alterations of RA axillary LNs
detectable by US; and this spectrum’s relationship with
the synovial inflammatory process and clinical phenotype,
before and on treatment with tumor necrosis factor
(TNF) inhibitors.
Methods
Recruitment criteria
Forty patients referred to the Biologic Therapy Unit
(Rheumatology Division) of the IRCCS Policlinico San
Matteo Foundation, Pavia, Italy were included (Table 1).
Patients were consecutively enrolled according to the
following criteria: fulfillment of the ACR 1987 classifica-
tion criteria for RA [25]; no current or previous treat-
ment with biologic therapies; inadequate response to
conventional synthetic DMARDs (csDMARDs) [26]; and
28-joint Disease Activity Score (DAS28) ≥ 3.2 [27]. Oral
glucocorticoids (≤7.5 mg/day of prednisone equivalents)
and nonsteroidal anti-inflammatory drugs were allowed.
Twenty volunteers (mean age ± standard deviation (SD):
53.2 ± 17.2 years, females: 75 %) free from chronic inflam-
matory arthropathies were enrolled as controls. The fol-
lowing exclusion criteria were applied to all participants:
history of malignancies; concomitant autoimmune or in-
fectious diseases; vaccinations and physical traumas in the
preceding 4 weeks; current treatment with peripheral va-
sodilators; and body mass index ≥ 35 (to limit potential
biases in physical examination of axillary LNs in obese
subjects).
Treatment protocol and follow-up
All recruited patients underwent standard clinical-
laboratory and US examinations on the same day within
1 week before biologic therapy introduction (baseline).
Thirty-five patients starting treatment with a TNF inhibi-
tor on stable csDMARD background for ≥3 months
(adalimumab, n = 25; etanercept, n = 7; certolizumab
pegol, n = 2; golimumab, n = 1) were considered for a
prospective proof-of-concept analysis with complete ex-
aminations at weeks 4 and 24. Follow-up monitoring and
treatment decisions were based on standard of care, with-
out knowledge of study findings. By the end of follow-up,
four patients discontinued the biological DMARD due
to adverse events (n = 3) or surgery (n = 1). At week 24,
patients were categorized as good vs moderate/nonre-
sponders according to the DAS28 and the European
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League Against Rheumatism (EULAR) response criteria
[27]. Patients switching to a different biologic due to
primary failure (n = 1) before week 24 were considered
nonresponders.
Joint PDUS
Joint PDUS was performed by a single experienced
rheumatologist ultrasonographer, unaware of clinical and
LN PDUS data, using a GE Logiq 9 scanner (General
Electrics Medical Systems, Milwaukee, WI, USA) with a
multifrequency linear array transducer (8–15 MHz), ac-
cording to the EULAR guidelines [28]. A 12-joint as-
sessment model, including transverse and longitudinal
scanning of the dorsal view of bilateral wrists (radiocarpal,
ulnocarpal, radioulnar, and midcarpal joints) and meta-
carpophalangeal joints (I–V), was applied [29, 30]. Power
Doppler (PD) settings were calibrated to maximise
sensitivity as described previously [30] and taken as
constant for the same joint in different patients.
Gray-scale (GS) (synovial hypertrophy and/or synovial
fluid according to the OMERACT definitions [31]) and
synovial PD were graded in each joint through independ-
ent semiquantitative (0–3) scales [29, 32]. Two cumulative
indices (12-joint GS index and 12-joint PD index) were
then calculated at each US assessment as the bilateral sum
of either GS or PD grades obtained from each joint (range
0–36) [29, 32].
Axillary LN PDUS: methods and settings
LN PDUS was performed with the same scanner and
transducer adopted for joint US by a single radiologist
with >5 years’ experience in breast-axillary sonography,
having no access to subject category (RA control), clin-
ical, and joint PDUS data. US examination started, after
5 minutes of rest in a supine position, from the lower
part of the axilla and continued upward toward the axil-
lary fossa (pectoral, central, subscapular, and lateral re-
gions) through a maximum scanning time of 5 minutes
per side. PD sonography was performed using standard-
ized settings calibrated for high sensitivity with a low wall
filter to allow detection of vessels with low blood flow.
The pulse repetition frequency was 800 Hz and medium
persistence was used. Color gain was set just below the
level at which noise artifacts appeared [33].
Axillary LN PDUS: parameters and grading
Each LN was studied with two-plane scanning. B-mode
images (with electronic measurements) and videos of the
dynamic PD assessment were then recorded for the ana-
lysis of LN volume, structure of the lymphocyte-rich
cortex and local perfusion.
Lymph node volume (LNV) was estimated by the el-
lipsoid formula 4/3π a2b, where b is the radius on the
greatest detected dimension (LN long axis (LA)) and a is
the radius on its largest orthogonal axis (LN short axis
(SA)) [34] (Fig. 1a). Lymph node cortical width (LNCW)
was defined as the maximum cortical measurement (from
the medulla–cortex interface to the capsule) parallel to
the LN axes [35] (Fig. 1b). LNV and LNCW were mea-
sured as continuous variables and converted into robust
(0–3) semiquantitative scores set on the upper limit of
normal (ULN, mean value + 2SD of controls [36]) as the
reference threshold: LNV grade 0 = normal (≤0.65 cm3,
ULN), grade 1 =mild LN hypertrophy (>1 ≤ 2 ULN), grade
2 =moderate (>2 ≤ 3 ULN), and grade 3 = high (>3 ULN);
and LNCW grade 0 = normal (≤4 mm, ULN), grade 1 =
mild cortical expansion (>4 ≤ 5 mm), grade 2 =moderate
(>5 ≤ 6 mm), and grade 3 = high (>6 mm).
Vascular perfusion was graded directly on a semiquan-
titative scale [37] based on the progressive degree of PD
signal [38] detectable within the LN cortex (central and
Table 1 Demographic and clinical characteristics of the patient
population at baseline
n = 40 patients
Age (years), mean (SD) 54.6 (14)
Females, n (%) 32 (80)
Disease duration (months), median (IQR) 38 (19–115)
DAS28, mean (SD) 4.87 (0.84)
SJC28, median (IQR) 4 (1.5–5.5)
TJC28, median (IQR) 8 (4–12.5)
VAS PtGA (mm), median (IQR) 65 (50–80)
HAQ-DI, median (IQR) 1.125 (0.75–1.5)
ESR (mm/1 h), median (IQR) 22 (18–36.5)
CRP (mg/dl), median (IQR) 0.9 (0.3–2.75)
12-joint GS index, median (IQR) 13 (8.5–18.5)
12-joint PD index, median (IQR) 2 (0–5.5)
IgM RF positive, n (%) 26 (65)
IgM RF titer (U/ml), median (IQR)a 85 (42.5–274)
IgG ACPA positive, n (%) 27 (67.5)
IgG ACPA titer (U/ml), median (IQR)a 66 (27.2–287.5)
Erosive disease, n (%)b 23/32 (71.9)
Current treatment with MTX, n (%) 36 (90)
Receiving corticosteroids, n (%) 31 (77.5)
Receiving NSAIDs, n (%) 9 (22.5)
Number of previous csDMARDs, median (range) 1 (0–3)
aRF or ACPA titers in RF-positive or ACPA-positive patients respectively. ACPA
titers > 340 U/ml were not diluted further
bHands and feet X-ray data not available in eight patients
SD standard deviation, IQR interquartile range, DAS28 Disease Activity Score in
28 joints, SJC28 swollen joint count in 28 joints, TJC28 tender joint count in 28
joints, VAS visual analogue scale, PtGA patient’s global assessment, HAQ-DI
Health Assessment Questionnaire disability index, ESR erythrocyte sedimentation
rate, CRP C-reactive protein, GS gray scale, PD power Doppler, RF rheumatoid
factor, ACPA anti-citrullinated peptide antibodies, MTX methotrexate, NSAID
nonsteroidal anti-inflammatory drug, csDMARD conventional synthetic
disease-modifying anti-rheumatic drug
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peripheral LN regions according to Steinkamp et al.
[37]): grade 0 = absent/minimal cortical flow (reference
for calibration: 0–1 PD+ cortical signals), Grade 1 =mild
(2–3), grade 2 =moderate (4–5), and grade 3 = high (≥6)
(Fig. 1c). Videos of the dynamic assessment are available
in Additional files 1, 2, 3, and 4. PD grades were assigned
independently (through consensus for discrepancies) by
two trained radiologists blind to subject category, clinical-
joint US data, and chronological order of the records.
For each individual, three bilateral cumulative indices
(LNV index, LNCW index, LNPD index) were then cal-
culated as the sum of the maximum grade of either
LNV, LNCW, or LN PD detected in the right and left
axilla (range 0–6). Patients without detectable LN were
assigned score 0.
LN PD grading reliability and digital image analysis
Within-scan inter-reader reliability of the LN PD grading
was preliminary evaluated after two calibration sessions
on external cases, by comparing the independent scores
of the two raters on a set of 40 videos randomly selected
by a study investigator from baseline examinations
[39]. Within-scan intra-reader reliability was assessed
by blinded rescoring of the same videos in a different
order 3 months later.
Quantitative analysis of the LN PD signal was per-
formed by digital image analysis (DIA) [33, 37]. Three
snapshots from each video were captured at 5-second in-
tervals by an experienced operator unaware of the semi-
quantitative grade. The mean percentage of color pixels
(color fraction (CF)) relative to the pixels of the total LN
area (selected manually as region of interest (ROI)) was
calculated by ImageJ (NIH, MD, USA), and defined as the
PD relative signal.
Statistical analyses
Demographic and clinical data were presented with mean
and SD, median and interquartile range (IQR), or relative
frequencies, as appropriate. Reliability of LN PD grading
was calculated by exact agreement and weighted kappa
statistics. Differences between groups were compared by
Mann–Whitney test and chi-square statistics. Correlations
between LN US and patients’ variables were computed by
Spearman’s rho correlation coefficients. Treatment effects
on joint/LN US characteristics at 4 and 24 weeks were
investigated by Friedman test with multiple-comparison
post-hoc testing. Longitudinal relationships between
Fig. 1 B-mode and power Doppler parameters assessed in axillary LNs by ultrasonography. a Representative image of an axillary LN showing the
short axis (SA) and long axis (LA) used for volume calculation (see Methods for description of the formula). b Representative images of the same
axillary LN showing three independent cortical measurements parallel to LN axes (upper, middle, and lower panels). The major of the cortical
measurements (presented in the upper panel) is defined as lymph node cortical width (LNCW). The capsule, the hypoechoic cortical area (cortex),
and the hyperechoic medullary region (medulla) of the LN are outlined. c Representative images of the PD grading system. Four different axillary
LNs characterized by progressive PD grades with progressive involvement of the cortical region are shown. White arrows indicate the number of
PD-positive signals in the cortex. VH vascular hilum (anatomic entry site of blood vessels into the node)
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changes in LN scores and joint US parameters or
DAS28 (external responsiveness) was assessed by linear
regression [40]. Predictive analyses for response to ther-
apy were performed by logistic regression adjusted for
possible confounders. All statistics were based on
MedCalc® version 12.7.0.0, and the level of significance
was set at 0.05.
Results
Reliability of nodal perfusion semiquantitative assessment
To evaluate the applicability of the semiquantitative
grading system devised for LN PD measurement, its
precision and relationship with digital analysis of LN
vascularity was preliminarily scrutinized in a selection
of videos.
Reliability exercises showed good strength of agreement
with weighted kappa values of 0.77–0.84 and exact agree-
ment of 75–80 % for inter-rater and intra-rater assess-
ments respectively. Objective analysis of PD relative signal
(% of total area of the node covered by PD+ vessels) quan-
titatively measured by DIA on static frames confirmed a
linear relationship with raters’ discrimination of grades
(p < 0.001; Kruskal–Wallis test). More details of grading
reliability and digital image analysis are presented in
the graphs available in Additional file 5.
LN sonographic changes are restricted to a subset of
patients with active RA
Palpable axillary LNs were identified in 9/40 RA patients
(22.5 %; median LN number (range): 0 (0–3)) and in 3/20
controls (15 %; 0 (0–1)). Blind US assessments performed
on the same day proved highly increased sensitivity, allow-
ing LN measurement in 36/40 patients (90 %) and 17/20
controls (85 %), without significant differences in terms of
LN number between groups (3 (0–9) vs 2 (8–0); p = 0.327;
Mann–Whitney test). Clear-cut heterogeneity was instead
captured through the application of the semiquantitative
gradings. Increased perfusion, global hypertrophy, and
cortical enlargement compared with controls were indeed
recognized in a variable number of axillary stations in
patients with RA, and determined significant sonographic
differences, at population level, between patients and
controls (LNV index, median (range): 0 (0–6) vs 0 (0–0),
p = 0.009; LNCW index: 0 (0–6] vs 0 (0–0), p = 0.009;
LNPD index: 1 (0–6) vs 0 (0–2), p = 0.039; Mann–Whit-
ney test). Similar results were obtained when morpho-
logical parameters were analyzed as continuous variables
taking into account the LN with maximum value in each
subject: LNV, median (range): 0.43 cm3 (0.1–5.1) vs
0.18 cm3 (0.1–0.6), p = 0.004; LNCW: 3 mm (1.3–10.2) vs
2.6 mm (1.3–3.7), p = 0.053 (Mann–Whitney test).
Within the RA group, nodal alterations were not uni-
formly distributed. Rather, they clustered within a tangible
patient subgroup in which multiple nodes were frequently
involved (Fig. 2a). The degree of variability captured by
each cumulative index is shown in Fig. 2b.
LN sonographic characteristics are partially influenced by
active synovitis in ipsilateral joints
Neither the number of detected LNs nor any of the LN
indices was related to IgG anti-citrullinated protein anti-
bodies or IgM rheumatoid factor titers in the whole group
or in seropositive cases (Table 2), and no significant differ-
ences were present between patients stratified according to
autoantibody positivity (data not shown). No relationship
was observed between LN parameters and the DAS28,
acute phase reactants, patient’s reported clinical/functional
outcome measures (data not shown), and objective or
semiobjective clinical assessment of joint involvement
(Table 2).
On the contrary, when sensitive PDUS imaging of the
synovium was applied, significant correlations were con-
sistently detected both for GS and PD indices (Table 2).
Correlations between synovial PD and LN scores were
confirmed and strengthened over ipsilateral compartments,
but lost across contralateral sides (Table 2), pointing to ac-
tive regional joint pathology as a trigger for the observed
sonographic changes in axillary nodes.
Despite this general agreement, however, PDUS im-
aging of the joints and axillary LNs did not appear to
provide overlapping information. Evidence for LN param-
eters exceeding the threshold of controls was restricted to
16/40 patients (40 %) vs 25/40 cases (62.5 %) in which ac-
tive (PD+) synovitis was detected (p = 0.073; chi-squared
test). Even within patients characterized by moderate to
high joint PD scores (≥4; median value of the PD score
among PD+ subjects), a sizable proportion of the cases
(6/14, 42.9 %) displayed LN parameters strictly below
the normality cutoff value, suggesting that active synovitis
and LN remodeling were cross-sectionally captured as
correlating but not redundant processes.
LN alterations are responsive to TNF blockade
To challenge these data from a dynamic perspective, plas-
ticity of baseline LN status was examined across 24 weeks,
addressing its relationship with synovitis changes and dis-
ease activity variations upon anti-TNF treatment.
TNF inhibition induced a prompt response at joint level,
with early and stable effects on synovial PD+ alterations
(12-joint PD index, median (IQR): baseline, 5 (2–11); week
4, 1.5 (0–8), p < 0.01 vs baseline; week 24, 3 (0–4), p < 0.01
vs baseline; Friedman test and post-hoc analysis for pair-
wise comparisons, n = 18 with 12-joint PD index > 0 at
study entry). Parallel assessment of the axillary LNs re-
vealed average stability of the sonographic pattern in the
short term, but could prove its sensitivity to change, show-
ing reduction at 24 weeks of the vascular, volumetric, and
cortical scores in patients displaying abnormal parameters
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at baseline (Fig. 3a). No significant LN modifications
(average score upregulation), at any time point, were in-
stead induced by anti-TNF in patients with pretreatment
LN indices within the range of controls (data not shown).
External responsiveness, tested against the joint PD
index in the whole cohort, confirmed a positive relation-
ship between axillary LN and ipsilateral joint change
scores at 24 weeks (ΔLNPD: R2 = 0.15, p = 0.035; ΔLNV:
R2 = 0.32, p = 0.001; ΔLNCW: R2 = 0.30, p = 0.002; linear
regression), but not at 4 weeks (data not shown). Similar,
although less systematic, results were obtained assessing
changes in DAS28 (Fig. 3b, c).
Low baseline LN scores are negatively associated with
clinical response to TNF inhibitors
At 24 weeks, 17 out of 31 patients (54.8 %) achieved a
good EULAR response (11/17 reaching remission accord-
ing to the DAS28) [27], whilst 14 (45.2 %) were moderate/
nonresponders. As expected, retrospective evaluation of
patients with different treatment outcomes failed to reveal
any significant difference in baseline DAS28, patient’s as-
sessment of disease activity, the 28-tender/swollen joint
counts, or US synovitis degree (GS and PD indices) (data
not shown and Fig. 4a, b).
Of note, consistent diversity could instead be captured
through US imaging of the LNs, as inferred by the sharply
lower number of detectable LNs (median (IQR): 2 (1–3) vs
4 (2–5.25), p = 0.017; Mann–Whitney test) and the lower
perfusion scores observed in the moderate/nonresponder
group (Fig. 4a, b). Pretreatment LNPD index = 0 (i.e., no
cortical PD signal bilaterally) discriminated prospective RA
patients characterized by a significant lower reduction in
the DAS28 during follow-up (Fig. 4c), turning out to be a
negative predictor of good EULAR response, independent
of joint PD grade (odds ratio = 0.04, 95 % confidence
interval = 0.01–0.35, p = 0.004; logistic regression). This
result remained significant even after adjustment for
age, sex, disease duration, glucocorticoid comedication,
and baseline DAS28. Neither the LNV index nor the
LNCW index showed similar associations.
Discussion
We demonstrate that superficial LNs can undergo
PDUS-measurable structural and perfusion changes in
Fig. 2 Ultrasonographic characteristics of axillary LNs in rheumatoid arthritis (RA) patients at baseline and in controls. a Map of ultrasonographic
characteristics of all examined LNs. Each individual LN (indicated under the map, n LN) is graded 0–3 for lymph node volume (LNV), lymph node cortical
width (LNCW), and lymph node power Doppler (LNPD) (see Methods for description of grading system). Individual LNs of each single subject are grouped
together using map separators (vertical black lines inside the map separate different subjects). White vertical bars indicate subjects in whom no measurable
LNs were found. RA patients with LNs displaying LNV, LNCW, and LNPD grades exceeding the threshold of healthy controls (HC) are clustered together on
the right side of the map. Note the restriction of LN alterations in a patient subgroup. b Distribution of HC and RA patients according to the LNV, LNCW,
and LNPD cumulative indices (sum of maximum detected grade for each parameter in the right and left axilla, see Methods for description). Note the
differences between RA patients and HC and the degree of variability captured by each index (presented in separate graphs)
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course of RA; that these changes reflect the existence of
an ongoing interactivity with peripheral inflamed sites;
and that quantitative analysis of LN status may provide
specific information, not captured by standard assess-
ment of the joint. Collectively, these data offer first-time
indication of the rationale of PDUS evaluation of the LN
as a complementary platform for assessment of the dis-
ease and lend direct support to the role of the JLS as a
component of RA inflammatory process.
Hand joints and wrists represent the most valuable site
for clinical, US, and radiographic examinations across
progressive phases of the disease. Based on this concept,
we designed this study focusing on the axillary LNs, an
easily traceable lymphoid complex receiving terminal
lymphatic drainage from the whole forearm, both directly
(through deep lymphatics) and across the epitrochlear
stations, through superficial lymphatics of the medial
compartment [10, 41].
To delineate the actual spectrum of axillary LN sono-
graphic variability, we developed a semiquantitative grading
approach and exploited it to measure the structural and
functional status of individual LNs, focusing on parameters
subjected physiologically to dynamic changes (volume, cor-
tical morphology, and local perfusion). Comparative ana-
lyses between active RA patients and healthy individuals
proved the discriminative capacity of the adopted scoring
Table 2 Correlations between lymph node indices and patient characteristics at baseline
Spearman’s rho correlation coefficient (95 % CI)
LNV index LNCW index LNPD index
Autoimmune status
IgG ACPA (U/ml)a −0.07 (−0.38 to 0.25)
p = 0.677
−0.16 (−0.45 to 0.16)
p = 0.321
−0.04 (−0.35 to 0.27)
p = 0.790
(ACPA-positive patients) 0.04 (−0.41 to 0.47)
p = 0.874
−0.20 (−0.59 to 0.27)
p = 0.402
−0.12 (−0.54 to 0.34)
p = 0.605
IgM RF (U/ml) −0.01 (−0.33 to 0.30)
p = 0.936
0.05 (−0.27 to 0.36)
p = 0.752
0.09 (−0.23 to 0.40)
p = 0.568
(RF-positive patients) 0.08 (−0.40 to 0.52)
p = 0.760
0.20 (−0.29 to 0.61)
p = 0.414
0.23 (−0.27 to 0.63)
p = 0.361
Joint assessment—clinical
TJC28 0.01 (−0.30 to 0.33)
p = 0.945
0.01 (−0.30 to 0.33)
p = 0.929
−0.02 (−0.33 to 0.30)
p = 0.910
TJC (ipsilateral)b, c −0.02 (−0.34 to 0.29)
p = 0.876
0.00 (−0.32 to 0.31)
p = 0.994
−0.07 (−0.38 to 0.25)
p = 0.656
SJC28 0.14 (−0.18 to 0.44)
p = 0.394
0.24 (−0.08 to 0.52)
p = 0.142
0.24 (−0.08 to 0.51)
p = 0.147
SJC (ipsilateral)b, c 0.15 (−0.17 to 0.44)
p = 0.366
0.25 (−0.07 to 0.53)
p = 0.121
0.21 (−0.11 to 0.50)
p = 0.189
Joint assessment—PDUS
12-joint GS index 0.30 (−0.02 to 0.56)
p = 0.063
0.33 (0.02–0.59)
p = 0.039
0.36 (0.05–0.60)
p = 0.026
GS index (ipsilateral)b 0.15 (−0.17 to 0.45)
p = 0.347
0.39 (0.08–0.62)
p = 0.015
0.25 (−0.06 to 0.53)
p = 0.117
GS index (contralateral) 0.05 (−0.27 to 0.36)
p = 0.767
0.21 (−0.11 to 0.49)
p = 0.204
0.14 (−0.18 to 0.44)
p = 0.392
12-joint PD index 0.46 (0.17–0.68)
p = 0.003
0.31 (0.00–0.57)
p = 0.053
0.35 (0.04–0.60)
p = 0.029
PD index (ipsilateral)b 0.40 (0.10–0.64)
p = 0.011
0.42 (0.12–0.65)
p = 0.007
0.36 (0.05–0.61)
p = 0.024
PD index (contralateral) 0.16 (−0.17 to 0.45)
p = 0.340
0.16 (−0.17 to 0.45)
p = 0.342
0.19 (−0.13 to 0.48)
p = 0.235
p <0.05 values are highlighted bold
aACPA titers >340 U/ml were not further diluted
bCorrelations between LN and joint parameters in nondominant arm
cJoint count restricted to I–V metacarpophalangeal joints, I–IV proximal and thumb interphalangeal joints, wrist, elbow, shoulder
CI confidence interval, LNV lymph node volume, LNCW lymph node cortical width, LNPD lymph node power Doppler, ACPA anti-citrullinated peptide antibodies,
RF rheumatoid factor, TJC28 tender joint count in 28 joints, SJC28 swollen joint count in 28 joints, PDUS power Doppler ultrasonography, GS gray scale,
PD power Doppler
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system at population level, and demonstrated the existence
of measurable inter-patient heterogeneity for all parameters
analyzed.
Cross-sectional detection of differences in patients
with long-standing disease could be theoretically related
to either active or anamnestic events, including the direct
input of ongoing inflammation from peripheral joints, the
effect of therapy, or the outcome of a stable pathologic
imprinting [23, 42]. Our results based on simultaneous as-
sessment of the LN and synovial PD (a sensitive readout
of active inflammation in the joint) [43] could capture the
influence of the former through four convergent proof-of
concepts: the significant correlation between LN scores
and synovial Doppler signal; the specific preservation of
these correlations on ipsilateral compartments; the pos-
sible reduction of LN alterations upon anti-TNF treat-
ment; and the long-term relationship between LN and
synovial PD change scores.
These data thus indicate the possible preservation of
dynamic interactivity between the joint and the draining
LN in established RA, an ancillary path that may contrib-
ute to perpetuation of the immune-pathologic process be-
yond preclinical and early phases of the disease [44]. US
detection of altered structural and perfusion scores in
axillary nodes might therefore be a sign of effective
lymphatic drainage in the context of an active joint in-
flammatory process, a model that fits with the possible
transfer of joint-derived inflammatory mediators in RA
lymph [12] and their role in LN hypertrophy and feed
arteriole expansion in vivo [45].
If, on one side, these data provide evidence of the im-
pact of peripheral inflammation on LN challenge, then,
on the other, the analysis of single individuals demon-
strated that active synovitis in hands and wrists was not
necessarily coupled to the expression of US changes in
the axillary nodes. Despite moderate-to-high disease activ-
ity, LN alterations were indeed clustered within a patient
subgroup, more restricted compared with the one in
which PD+ synovitis was observed. Of note, this partial
discrepancy turned out to be relevant and sharper
when disease evolution was analyzed. In particular,
despite no predictive information inferable from US or
clinical evaluation of the joints [46], extension of the
assessment to the LNs allowed capture of differences
regarding treatment outcome. Lower LN numbers and
perfusion scores at baseline, suggestive of a defective
response, were indeed significantly related to poorer
disease control.
Fig. 3 Responsiveness of axillary LN ultrasonographic characteristics. a Variation of the subject-related cumulative indices for lymph node power
Doppler (LNPD index), volume (LNV index), and cortical width (LNCW index) in patients with RA at earlier (4 weeks) and later (24 weeks) time
points after institution of treatment with anti-TNF. Median values (circles) and 25th–75th percentiles (error bars) are presented for each time point.
In patients with baseline LN indices above the threshold of healthy controls (HC) (horizontal dotted lines) significant reductions were observed
after 24 weeks but not 4 weeks. *p <0.05, **p <0.01; Friedman test and post-hoc analysis for pairwise comparisons (LNPD index, n = 10; LNV index,
n= 7; LNCW index, n= 8). b, c Scatter diagrams and regression lines showing the relationship between variations (Δ) from baseline of the LN indices
(LNPD, LNV, LNCW) and the 28-joint Disease Activity Score (DAS28) at 4 weeks b and 24 weeks c. Each dot represents one patient (n= 30 with complete
assessments at baseline, week 4, and week 24). Positive values on the axes of the graphs indicate reduction of the parameters (positive Δ). R2
linear regression’s coefficient of determination, LNCW lymph node cortical width, LNV lymph node volume, TNF tumor necrosis factor
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Recent elegant experiments in the murine system de-
lineate a model that may give a putative explanation of
these results. It has indeed been shown that lymphatic
drainage in the course of arthritis can be impaired, and
that LNs draining inflamed joints can undergo a process
of “collapse”. This phenomenon is related to transloca-
tion of specific B-cell subsets (Bin, B cells in inflamed
nodes) in the paracortical sinuses, and is coupled to de-
creased PD signal and defective lymphatic flow [47, 48].
Of relevance, LN Bin, whose presence in humans has
been proved recently [49], can be removed by systemic
B-cell depletion [47], but are marginally affected by anti-
TNF [50]. Introduction of treatment in a phase in which
a central lymphatic road-block is active might thus limit
some of the beneficial effects of anti-TNF that include
peripheral lymphangiogenesis [51] and increased lymph-
atic contraction [50].
We are aware that no conclusions can be drawn on
the LN as a biomarker of clinical response to treatment
due to the small sample size of this proof-of-concept
study. Nevertheless, our cross-sectional and longitudinal
analyses consistently demonstrate that PDUS assessment
of the joint and the draining LN may provide different
perspectives on local pathology. This observation is import-
ant, because it defines the rationale of a novel analytical
approach to peripheral disease, based on integrated assess-
ment of arthritis and nodal involvement.
Another relevant aspect of this study is the application
of a quantitative tool for the sonographic characterization
of superficial LNs in an inflammatory context. Because
this approach appeared successful for the aims of the
current investigation, it is important to emphasize also its
possible implementation. In particular, due to the lack of
an accessible gold standard for the construct “LN reactiv-
ity”, the scores we applied were based on progressive
thresholds expressing differences in individual morpho-
logical characteristics. The development of composite pa-
rameters, based on parallel histopathologic-US analyses
and designed on an immunological criterion, is among the
potential lines of research that may stem from our obser-
vations. Additional studies are also warranted to directly
compare US with other imaging approaches in order to
define performance/limitations of the technique in the
assessment of deep axillary stations and more distal
structures, such as epitrochlear LNs.
Conclusions
In this study, we demonstrate the applicability of PDUS
to measure and decipher intrinsic aspects of RA path-
ology beyond conventional assessment of the joint. The
Fig. 4 Baseline joint and axillary LN ultrasonographic characteristics in relationship to clinical outcome. a Box-and-whisker plots showing baseline
differences in the 12-joint power Doppler (PD) index (upper panel) and the lymph node (LN) PD index (bottom panel) in patients with RA stratified
according to the European League Against Rheumatisms (EULAR) response criteria at 24 weeks following institution of anti-TNF treatment.
Mann–Whitney test (n = 31). b Bar charts showing the prevalence of different scores at baseline for the 12-joint PD index (upper panel) and
LNPD index (bottom panel). Each score is presented with a different gray-scale tonality. Enrichment of LNPD index score = 0 (white) in patients
failing to achieve EULAR good response. c Mean (95 % confidence interval) of the 28-joint Disease Activity Score (DAS28) during follow-up in
patients stratified according to the presence/absence of PD activity in the joints (upper panel) and LN (bottom panel) at baseline. Different clinical
dynamics across 24 weeks of patients exhibiting LNPD index score = 0. Repeated-measures ANOVA in patients with complete assessments at baseline,
week 4, and week 24 (LNPD index = 0, n = 12; LNPD index > 0, n = 18). TNF tumor necrosis factor
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integrated analysis of the joint-draining LN complex
may represent a novel approach to better delineate the
characteristics and outcomes of peripheral inflamma-
tion in patients with RA.
Additional files
Additional file 1: Assessment in PD mode of an axillary LN graded 0 for
perfusion. A static frame of this video is shown in Fig. 1c (upper panel)
(WMV 7010 kb)
Additional file 2: Assessment in PD mode of an axillary LN graded 1 for
perfusion. A static frame of this video is shown in Fig. 1c (mid-upper panel)
(WMV 2554 kb)
Additional file 3: Assessment in PD mode of an axillary LN graded 2 for
perfusion. A static frame of this video is shown in Fig. 1c (mid-lower panel)
(WMV 2350 kb)
Additional file 4: Assessment in PD mode of an axillary LN graded 3 for
perfusion. A static frame of this video is shown in Fig. 1c (lower panel)
(WMV 5432 kb)
Additional file 5: Figure S1. Showing LN PD grading reliability and
digital image analysis. Bar charts showing interrater (A) and intrarater (B)
agreement of the LN power Doppler (PD) grading system (n = 40 LN
videos). C Representative images of three serial snapshots of an axillary
LN adopted for the assessment of PD relative signal by digital image
analysis (see Methods for description). Yellow perimeter (region of interest
(ROI)) and the red area (color fraction (CF)) represent the whole LN area and
the PD-positive area used for pixel calculation. D Dot plot showing the
calculated PD relative signal and its relationship with the semiquantitative
PD grades assigned by raters (independent rating with discrepancies resolved
by mutual agreement) (n = 40 LN videos). Each black circle represents
one LN. Red circles and horizontal lines show the median values of the
PD relative signal in each grade. **p < 0.01, Kruskal–Wallis test and
post-hoc analysis (TIF 2865 kb)
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